Intuitive Surgical, Inc.

Intuitive Surgical, Inc.

ISRGNYSE / NASDAQHealthcareLarge cap

$399.05-$8.19 (-2.0%)

Last close · Data as of Nov 20, 2026

Market cap
$148.3B
P/E
51.9x
EV / EBITDA
39.3x
Revenue
$10.1B
Net margin
28.4%
ROCE
16.5%

-27.7% over the last year

Intuitive Surgical, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-8.9%
3M
+6.6%
6M
-11.1%
1Y
-27.7%
5Y
+14.5%

52-week range

Day change -$8.19 (-2.0%) from $407 to $399 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ISRG, bought on each weekday since 2021.

News & filings

What Intuitive Surgical filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating margin of 29.3% against a peer median of 19.6%.

Concerns (1)

  • The P/E of 51.9 is 104% above the peer median of 25.5.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally.

Read moreShow less

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.

Sector
Healthcare
Shares outstanding
355.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$148.3B
P/E
51.9x
P/B
8.3x
EV / EBITDA
39.3x
EV / Sales
14.2x
P/S
14.7x
52-week high
$592.85
52-week low
$332.02

Profitability

Operating margin
29.3%
Net margin
28.4%
EBITDA margin
36.0%
ROE
16.0%
ROCE
16.5%
ROA
14.0%
Asset turnover
0.49

Growth

Revenue
$10.1B
Revenue growth, 1Y
20.5%
Revenue CAGR, 3Y
17.4%
Free cash flow
$2.5B

Solvency

Current ratio
4.87
Debt / Equity
0.00
Debt / Assets
0.00
CFO / Net profit
1.06
Cash / Market cap
4.0%

Where the revenue went

Some FY2025 lines are not reported, so the ones that are appear as a table.

LineFY2025
Revenue$10.1B
Cost of revenue$3.4B
Gross profit$6.6B
Operating expenses$3.7B
Research and development$1.3B
Selling, general and administrative$2.4B
Operating income$2.9B
Interest and other$365.9M
Pretax income$3.3B
Tax and other$434.8M

Revenue and net profit

Revenue grew 20.5% in FY2025; net profit is the dashed line.

Intuitive Surgical, Inc. revenue and net profit by fiscal year
Intuitive Surgical, Inc. revenue and net profit by fiscal year
DateRevenue
FY2022$6.2B
FY2023$7.1B
FY2024$8.4B
FY2025$10.1B

Cash flows

FY2025: $3.0B from operations, $2.5B free after investment (dashed).

Intuitive Surgical, Inc. operating and free cash flow by fiscal year
Intuitive Surgical, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$1.5B$958.4M
FY2023$1.8B$749.6M
FY2024$2.4B$1.3B
FY2025$3.0B$2.5B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$10.1B+20.5%1Y
EBITDA
$3.6B+27.2%1Y
Cash from operations
$3.0B+25.5%1Y
Free cash flow
$2.5B+91.0%1Y
Revenue CAGR, 3Y
17.4%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$10.1B$3.6B—$2.5B—+20.5%—

Monthly returns

Month-by-month returns of ISRG across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$20.5B
Liabilities$2.5B
Equity$17.9B
Paid-in capital$10.8B
Retained earnings$7.0B
Minority interest$117.7M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ISRG highlighted.

P/E against peers

ISRG trades at 51.9x earnings against a peer median of 25.5x (a 104% premium).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Intuitive Surgical, Inc.ISRGthis companyP/E ↑ premium$148.3B51.9x8.3x16.0%39.3x
Thermo Fisher Scientific Inc.TMO$179.1B26.7x3.4x12.6%18.1x
Gilead Sciences, Inc.GILD$160.4B18.8x7.1x37.5%12.9x
Abbott LaboratoriesABT$158.1B24.2x3.0x12.5%13.5x
Pfizer Inc.PFE$146.4B18.8x1.7x9.0%12.5x
Danaher CorporationDHR$132.1B36.6x2.5x6.9%21.2x
CVS Health CorporationCVS$121.0B68.4x1.6x2.4%19.5x
Bristol-Myers Squibb CompanyBMY$115.6B16.4x6.3x38.2%10.0x
Stryker CorporationSYK$115.5B35.6x5.2x14.5%20.2x
Peer median—25.5x3.2x12.5%15.8x

Year-to-date ROI

ISRG since 1 January, against earlier years.

Historical volatility

ISRG's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Intuitive Surgical, Inc. operating margin by fiscal year
Intuitive Surgical, Inc. operating margin by fiscal year
DateOperating margin
FY202225.3%
FY202324.8%
FY202428.1%
FY202529.3%
LineFY2025
Cost of revenueCost Of Revenue$3.4B
Gross profitGross Profit$6.6B
Operating expensesOperating Expense$3.7B
Research and developmentResearch And Development$1.3B
Selling, general and administrativeSelling General And Administration$2.4B
Total expensesTotal Expenses$7.1B
Pretax incomePretax Income$3.3B

Learn while you research

Academy chapters picked for Intuitive Surgical, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 51.9, learn when high multiples are justified.6 min read
  3. 03 Growth Investing21% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →